Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting

NEXT STORY
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
PREV STORY
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sales growth accelerated – Full-year guidance raised

author_avatar
NASDAQ Market News

Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma

author_avatar
NASDAQ Market News

Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy™ (CNT) for Hypertension

author_avatar
NASDAQ Market News